Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV ...

Waters Corporation WAT shares are up on Wednesday as the company announced FDA clearance for its Onclarity HPV ...

The US FDA's approval of Waters' at-home cervical cancer screening kit marks a significant step in enhancing early detection and reducing fatalities. This move positively impacted Waters' stocks, ...

The life sciences and diagnostics company said Wednesday the regulator cleared its Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use.

According to the World Health Organization (WHO), in 2022 cervical cancer was the fourth most common cancer among women worldwide, with about 660,000 new cases. Studies project that cervical cancer ...

Add Yahoo as a preferred source to see more of our stories on Google. Cervical cancer screening is about to get a lot more convenient. That’s because the latest cervical cancer screening guidelines ...

The American Cancer Society has endorsed self-collected vaginal samples for cervical cancer screening — a change medical experts say will help expand access and improve detection. The updated ACS ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. In May 2025, for the first time ever, the U.S. Food and Drug Administration granted approval ...

The findings of a new study add to growing evidence that cotesting may offer limited clinical value despite its common use in ...

FDA-approved BD Onclarity HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4 with extended genotyping and end-to-end automated lab workflows. At-home self-collection ...